Bonesupport
BONE SUPPORT RECEIVES “BREAKTHROUGH DEVICE DESIGNATION” FOR CERAMENT® V FOR THE INDICATION OF BONE INFECTION
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces that the company's antibiotic eluting product CERAMENT® V has received categorization as a "breakthrough device" for the indication bone infection by the American Food and Drug Administration (FDA).
The categorization breakthrough device is assigned to products that are considered to provide a more effective treatment of severe medical conditions, where there is no comparable equivalent on the market. The categorization has been added to expedite the regulatory review of new medical devices and give patients faster access to new treatment options. CERAMENT® G has previously received breakthrough device designation for the indication's bone infection and trauma.
| Datum | 2023-10-16, kl 14:02 |
| Källa | MFN |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!